{"DataElement":{"publicId":"5629833","version":"1","preferredName":"Agent T-DM1 Administered Agent End Date","preferredDefinition":"The date T-DM1 therapy ended","longName":"3645343v1.0:2179511v1.0","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3645343","version":"1","preferredName":"Agent T-DM1 Administered","preferredDefinition":"information related to the administration of the agent T-DM1 (Trastuzumab emtansine; an antibody-drug conjugate consisting of the recombinant anti-epidermal growth factor receptor 2 HER2 monoclonal antibody trastuzumab conjugated to the maytansinoid DM1) to a patient.","longName":"2223333v1.0:3645341v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3645341","version":"1","preferredName":"Trastuzumab Emtansine Administered","preferredDefinition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.:The act of having given something (e.g., a medication or test).","longName":"C82492:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trastuzumab Emtansine","conceptCode":"C82492","definition":"An antibody-drug conjugate (ADC) consisting of the recombinant anti-epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab conjugated to the maytansinoid DM1 via a nonreducible thioether linkage (MCC) with potential antineoplastic activity. The trastuzumab moiety of this ADC binds to HER2 on tumor cell surfaces; upon internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/disassembly dynamics and inhibiting cell division and the proliferation of cancer cells that overexpress HER2. Linkage of antibody and drug through a nonreducible linker has been reported to contribute to the improved efficacy and reduced toxicity of this ADC compared to similar ADCs constructed with reducible linkers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0D28D6C-4B43-7D31-E040-BB89AD43648F","latestVersionIndicator":"Yes","beginDate":"2012-12-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-12-14","modifiedBy":"ONEDATA","dateModified":"2012-12-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D0D28D6C-4B54-7D31-E040-BB89AD43648F","latestVersionIndicator":"Yes","beginDate":"2012-12-14","endDate":null,"createdBy":"SHIDED","dateCreated":"2012-12-14","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2179511","version":"1","preferredName":"Agent End Date","preferredDefinition":"The date when agent usage ended.","longName":"AGT_END_DT","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"DATE","minLength":"10","maxLength":"10","minValue":null,"maxValue":null,"decimalPlace":null,"format":"MM/DD/YYYY","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008565","version":"1","preferredName":"Temporal concepts","preferredDefinition":"Time meaning: Like time, date, frequency, occurence,..etc","longName":"TEMPORAL_CONCEPTS","context":"SPOREs","contextVersion":"2.31","origin":null,"workflowStatus":"DRAFT NEW","registrationStatus":"Application","id":"B7822ECE-3F17-24F5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-25","endDate":null,"createdBy":"MEDVEDOH","dateCreated":"2003-02-25","modifiedBy":"SBREXT","dateModified":"2004-02-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2233081","version":"1","preferredName":"Date","preferredDefinition":"a particular day specified as the time something has, or will, happen.","longName":"C25164","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Date","conceptCode":"C25164","definition":"The particular day, month and year an event has happened or will happen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F90B5E56-BB15-0F45-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-09","modifiedBy":"ONEDATA","dateModified":"2005-06-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCBA97B-CAC3-5D7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"End Date","type":"Preferred Question Text","description":"End Date","url":null,"context":"NRG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"46645AEA-E1B5-17CF-E053-F662850ACFA7","latestVersionIndicator":"Yes","beginDate":"2017-01-18","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-01-18","modifiedBy":"SARAHB","dateModified":"2017-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}